---
title: "The public offering of TRANSTHERA was oversubscribed by nearly 3,419 times, with a winning rate of only 0.8% for one lot"
description: "TRANSTHERA's public offering was oversubscribed by nearly 3,419 times, with a one-hand winning rate of only 0.8%. The subscription multiple for the international offering was 0.97 times, and the numbe"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/245574988.md"
published_at: "2025-06-22T11:55:27.000Z"
---

# The public offering of TRANSTHERA was oversubscribed by nearly 3,419 times, with a winning rate of only 0.8% for one lot

> TRANSTHERA's public offering was oversubscribed by nearly 3,419 times, with a one-hand winning rate of only 0.8%. The subscription multiple for the international offering was 0.97 times, and the number of shares for the public offering increased to 3.057 million shares, accounting for 20% of the total offering. This global offering consists of 15.281 million shares, with an offer price of 13.15 yuan, and the expected net fundraising amount is 161 million yuan. Five cornerstone investors subscribed for a total of 130 million yuan in shares, which are expected to be listed on Monday (23rd)

TRANSTHERA-B (02617.HK) announced the results of its IPO, with the Hong Kong public offering receiving 3,419.87 times subscription, and the winning rate for one board lot (500 shares) at 0.8%. The international offering recorded 0.97 times subscription. After reallocation, the number of shares for the public offering has increased to 3.057 million shares, accounting for 20% of the total offering. The shares are expected to be listed on Monday (23rd).

The biopharmaceutical company TRANSTHERA-B is conducting a global offering of 15.281 million shares, with the public offering accounting for 10%. The offer price is HKD 13.15, raising a net amount of HKD 161 million. Five cornerstone investors, including Jiangbei Pharmaceutical, Canfite BioPharma (09926.HK), Huasheng Dunhang, Yaoshi Dihengxian, and Kelin An, collectively subscribed for HKD 130 million of the company's shares

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)
- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股异动：药捷安康-B 涨 16.21%，资金流向活跃，板块趋势引发市场关注？ | 药捷安康-B 涨 16.21%；三生制药跌 1.44%，成交额达到 1.3 亿港币；信达生物跌 1.01%，成交额达到 1.17 亿港币；康方生物跌 1.52%，成交额达到 70.04 百万港币；百济神州跌 1.14%，市值达到 2799  | [Link](https://longbridge.com/en/news/271050704.md) |
| SK 海力士高盛电话会：所有客户需求都无法满足，今年存储价格持续上涨 | SK 海力士在高盛电话会上释放强烈信号：存储行业已全面进入卖方市场。受 AI 真实需求驱动及洁净室空间受限影响，今年存储价格将持续上涨。公司透露目前 DRAM 及 NAND 库存仅剩约 4 周，且没有任何客户能完全满足需求。随着 2026  | [Link](https://longbridge.com/en/news/276505903.md) |
| 传言成真？英伟达对 OpenAI 的 “1000 亿美元投资” 最终 “打了三折” | 据报道，英伟达正接近敲定对 OpenAI 最高 300 亿美元的股权投资，取代此前官宣的 1000 亿美元合作框架。原有协议因条款分歧与内部疑虑未能落地，黄仁勋亦曾强调其不具约束力。此次新融资轮规模或超 1000 亿美元，OpenAI 估值 | [Link](https://longbridge.com/en/news/276507066.md) |
| 特朗普暗示违法征收的关税不退了，美财长称今年关税收入将 “基本保持不变” | 美国总统特朗普暗示不会退还被最高法院裁定违法的关税，预计 2026 年关税收入将保持不变。特朗普计划签署行政令，对全球商品加征 10% 进口关税，取代被推翻的关税。财长贝森特表示，政府将利用替代法律权力维持关税收入，强调国家安全和财政收入不 | [Link](https://longbridge.com/en/news/276494362.md) |
| 美财政部让步，拟修订主权财富基金税收提案，此前遭私募业警告 | 美国财政部正就一项针对主权财富基金和公共养老基金征税方式进行全面改革的提案作出让步。相关提案此前由美国国税局提出，拟更新税法第 892 条，将这些基金持有的多数美国债务投资归为商业活动，这将令其面临被征税的风险。此前，私募信贷和私募股权公司 | [Link](https://longbridge.com/en/news/276491732.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.